search
Back to results

ETCare: Safety and Preliminary Efficacy Trial

Primary Purpose

Respiratory Distress Syndrome, Newborn

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
#1 Respiratory Care Solution
Sponsored by
Intermountain Health Care, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Respiratory Distress Syndrome, Newborn focused on measuring Endotracheal Cares, Neonate, TAC's, Endotracheal Suctioning, Tracheal Aspirate Culture, Oral Cares, Neonate oxygen Therapy

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Be a patient in the NICU of either McKay-Dee Hospital or LDS Hospital.
  • Be <24 hrs old at the time of study entry.
  • Have an endotracheal tube in place.
  • Be expected, by declaration of the attending neonatologist, to have an endotracheal tube for at least the next 48 hrs.
  • Have the informed consent document signed by the parent or responsible guardian

Exclusion Criteria:

  • They have what the attending neonatologist judges to be a "lethal" congenital abnormality.
  • They have a condition that is likely (by judgment of the attending neonatologist) to require transfer to Primary Children's Medical Center before the endotracheal tube has been electively removed.

Sites / Locations

  • McKay-Dee Hospital Center
  • LDS Hospital Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

#1 Respiratory Care Solution

Arm Description

Low sodium physiologically based airway care solution.

Outcomes

Primary Outcome Measures

The incidence of adverse events related to administration.
Renal hematological and hepatic function.

Secondary Outcome Measures

Feasibility and immediate intolerance
Desaturation, bradycardia, tachydardia, hypotension, or hypertension or skin rashes.

Full Information

First Posted
May 12, 2008
Last Updated
September 18, 2012
Sponsor
Intermountain Health Care, Inc.
Collaborators
Deseret Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01688440
Brief Title
ETCare: Safety and Preliminary Efficacy Trial
Official Title
"ETCare": A Phase II, Safety and Preliminary Efficacy Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
June 2005 (undefined)
Primary Completion Date
September 2005 (Actual)
Study Completion Date
September 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Intermountain Health Care, Inc.
Collaborators
Deseret Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
When babies are sick, or are born prematurely, they sometimes need an endotracheal (ET) tube to assist their breathing and/or a nasal canula. The investigators must periodically irrigate the ET tube to prevent them from being plugged up by secretions. The investigators also, due to the drying effects of nasal canula, periodically moisten the nasal passages of babies. Presently 0.9% saline is the solution being used for moistening of the ET tube, nose, as well as oral cares will infant is not eating. However, scientists have recently learned that saline can destroy the body's natural antibacterial properties in the windpipe, nose, and mouth. The investigators have developed a new solution to be used in place of saline for endotracheal (ET), nasal, and oral cares. The investigators' new solution is patterned after the natural fluid in the windpipe, nose, and mouth. Study Hypothesis: Patients who receive ETCare will have no increase in adverse events related to its administration, compared with 0.9% saline. Patients who receive ETCare will have a lower proportion of tracheal aspirates where pathogens are reported. Patients who receive ETCare will have a lower proportion of tracheal aspirates where leukocytes are reported. Patients who receive ETCare will have fewer (risk-adjusted) days of supplemental oxygen.
Detailed Description
Normal saline (0.9% sodium chloride) is used by virtually all neonatal intensive care units to periodically irrigate the endotracheal tube of neonates who require mechanical ventilation. This practice is intended to reduce the risk that thick secretions will occlude the endotracheal tube. Normal saline is also occasionally used to periodically clear the nasal passages of neonates on nasal CPAP or nasal canula oxygen. It is also occasionally used as a means of periodically moistening the mouth of neonates who have an endotracheal tube in place, because the tube prevents lip apposition and results in a dry mouth. The problem with the current method of using normal saline for periodic endotracheal, nasal, and/or oral care is that high concentrations of sodium and chloride have recently been found to rapidly and completely inactivate the natural antimicrobial properties of tracheal effluent, nasal secretions, and saliva. Tracheal secretions, nasal secretions, and saliva contain potent antibacterial substances. One such that was recently described is a 37 amino acid peptide with widespread antimicrobial properties, termed "LL-37". It has recently been shown that 0.9% saline inactivates the antimicrobial properties of LL-37 and significantly damages the overall antibacterial actions of tracheal secretions, nasal secretions, and saliva. Further research has shown that the high sodium and chloride content of saliva of patients with cystic fibrosis inactivates the antimicrobial properties, thus partly explaining the high incidence of airway infections in these patients. Moreover, a family with deficient LL-37 has been described in Sweden, and these individual all have chronic gingivostomatitis and airway infections. Therefore, our current practice of instilling 0.9% sodium chloride likely inactivates the major innate anti-microbial defense system of the upper airway. Perhaps reducing immune capacity in the upper airway with this practice unwittingly contributes to the high incidence of upper airway infections among intubated neonates.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Distress Syndrome, Newborn
Keywords
Endotracheal Cares, Neonate, TAC's, Endotracheal Suctioning, Tracheal Aspirate Culture, Oral Cares, Neonate oxygen Therapy

7. Study Design

Primary Purpose
Prevention
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
#1 Respiratory Care Solution
Arm Type
Experimental
Arm Description
Low sodium physiologically based airway care solution.
Intervention Type
Other
Intervention Name(s)
#1 Respiratory Care Solution
Intervention Description
Respiratory care solution.
Primary Outcome Measure Information:
Title
The incidence of adverse events related to administration.
Description
Renal hematological and hepatic function.
Time Frame
To discharge home (about one month).
Secondary Outcome Measure Information:
Title
Feasibility and immediate intolerance
Description
Desaturation, bradycardia, tachydardia, hypotension, or hypertension or skin rashes.
Time Frame
Day of administration (one day)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be a patient in the NICU of either McKay-Dee Hospital or LDS Hospital. Be <24 hrs old at the time of study entry. Have an endotracheal tube in place. Be expected, by declaration of the attending neonatologist, to have an endotracheal tube for at least the next 48 hrs. Have the informed consent document signed by the parent or responsible guardian Exclusion Criteria: They have what the attending neonatologist judges to be a "lethal" congenital abnormality. They have a condition that is likely (by judgment of the attending neonatologist) to require transfer to Primary Children's Medical Center before the endotracheal tube has been electively removed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert D. Christensen, MD
Organizational Affiliation
Interountain Healthcare
Official's Role
Principal Investigator
Facility Information:
Facility Name
McKay-Dee Hospital Center
City
Ogden
State/Province
Utah
ZIP/Postal Code
84403
Country
United States
Facility Name
LDS Hospital Center
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84143
Country
United States

12. IPD Sharing Statement

Learn more about this trial

ETCare: Safety and Preliminary Efficacy Trial

We'll reach out to this number within 24 hrs